Highly potent half-sandwich iridium and ruthenium complexes as lysosome-targeted imaging and anticancer agents
- 9 October 2018
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 47 (44), 15772-15782
- https://doi.org/10.1039/c8dt02963f
Abstract
In this study, six half-sandwich luminescent iridium (Ir) and ruthenium (Ru) anticancer complexes bearing P^P-chelating ligands 1,2-bis(diphenylphosphino)benzene (dppbz) and 1,8-bis(diphenylphosphino)naphthalene (dppn) were synthesized and characterized via1H-NMR spectroscopy, 31P-NMR spectroscopy, mass spectrometry, elemental analysis and X-ray crystallography. All the complexes displayed more potent anticancer activity than cisplatin towards A549 lung cancer cells and HeLa cervical cancer cells, especially the most potent iridium complex Ir3, which was 73 times more potent than cisplatin against A549 cells. Different from cisplatin, no nucleobase adducts of Ir3 were detected. With the help of the self-luminescence of complex Ir3 and confocal microscopy, it was observed that Ir3 efficiently penetrated into the A549 cells via energy-dependent active transport, and specifically accumulated in lysosomes, affected the permeabilization of the lysosomal membranes and induced caspase-dependent cell death through lysosomal damage. Both apoptosis and autophagy of the A549 cells were observed. The reactive oxygen species (ROS) elevation, reduction of the mitochondrial membrane potential and cell cycle arrest at the G0/G1 phase also contributed to the observed cytotoxicity of Ir3. We demonstrate that these half-sandwich Ir and Ru anticancer complexes have different anticancer mechanism of action from that of cisplatin, which can be developed as potential multifunctional theranostic platforms that combine bioimaging and anticancer capabilities.Funding Information
- National Natural Science Foundation of China (21671118)
This publication has 62 references indexed in Scilit:
- Reduction of Quinones by NADH Catalyzed by Organoiridium ComplexesAngewandte Chemie-International Edition, 2013
- Organometallic Ruthenium and Iridium Transfer‐Hydrogenation Catalysts Using Coenzyme NADH as a CofactorAngewandte Chemie-International Edition, 2012
- Genetically Encoded Fluorescent Sensors for Intracellular NADH DetectionCell Metabolism, 2011
- Organometallic Half-Sandwich Iridium Anticancer ComplexesJournal of Medicinal Chemistry, 2011
- Recent developments in ruthenium anticancer drugsMetallomics, 2009
- Bioorganometallic chemistry—from teaching paradigms to medicinal applicationsChemical Society Reviews, 2008
- Classical and Non‐Classical Ruthenium‐Based Anticancer Drugs: Towards Targeted ChemotherapyEuropean Journal of Inorganic Chemistry, 2006
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005
- Antineoplastic activity and toxicity of an organometallic complex of ruthenium(II) in comparison with cis-PDD in mice bearing solid malignant neoplasmsEuropean Journal of Cancer and Clinical Oncology, 1984
- Synthesis, crystal structure, and dynamic behavior of tetra-.mu.-hydrido-.mu.-[1,2-bis(diphenylphosphino)ethane]-decacarbonyltetraruthenium, an isomer of (.mu.-H)4Ru4(CO)10(diphos) with a bridging diphos ligandInorganic Chemistry, 1980